Apellis (APLS) Pharmaceuticals announced its strategic priorities for continued growth across the business. Key highlights: SYFOVRE total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026; Strong EMPAVELI launch in C3G and primary IC-MPGN continues, with 267 new patient start forms in 2025; more than 5% market penetration following the first full quarter post-launch; Pivotal trials initiated for EMPAVELI in two additional nephrology indications, FSGS and DGF; Preliminary year-end cash and cash equivalents of approximately $466 million; projected revenues, cash and cash equivalents expected to be sufficient to fund operations to profitability
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $48 from $55 at Stifel
- Apellis Pharmaceuticals: Buy Rating Affirmed Amidst European Regulatory Milestones and Long-term Growth Potential
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre Potential
- Apellis announces NEJM published ‘positive’ Phase 3 EMPAVELI study data